272 related articles for article (PubMed ID: 34335961)
1. Orthogonal targeting of osteoclasts and myeloma cells for radionuclide stimulated dynamic therapy induces multidimensional cell death pathways.
Zheleznyak A; Mixdorf M; Marsala L; Prior J; Yang X; Cui G; Xu B; Fletcher S; Fontana F; Lanza G; Achilefu S
Theranostics; 2021; 11(16):7735-7754. PubMed ID: 34335961
[No Abstract] [Full Text] [Related]
2. Induction of complementary immunogenic necroptosis and apoptosis cell death pathways inhibits cancer metastasis and relapse.
Egbulefu C; Black K; Su X; Karmakar P; Habimana-Griffin L; Sudlow G; Prior J; Chukwu E; Zheleznyak A; Xu B; Xu Y; Esser A; Mixdorf M; Moss E; Manion B; Reed N; Gubin M; Lin CY; Schreiber R; Weilbaecher K; Achilefu S
Res Sq; 2024 Mar; ():. PubMed ID: 38558990
[TBL] [Abstract][Full Text] [Related]
3. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
Tai YT; Chang BY; Kong SY; Fulciniti M; Yang G; Calle Y; Hu Y; Lin J; Zhao JJ; Cagnetta A; Cea M; Sellitto MA; Zhong MY; Wang Q; Acharya C; Carrasco DR; Buggy JJ; Elias L; Treon SP; Matsui W; Richardson P; Munshi NC; Anderson KC
Blood; 2012 Aug; 120(9):1877-87. PubMed ID: 22689860
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.
Shay G; Tauro M; Loiodice F; Tortorella P; Sullivan DM; Hazlehurst LA; Lynch CC
Oncotarget; 2017 Jun; 8(26):41827-41840. PubMed ID: 28611279
[TBL] [Abstract][Full Text] [Related]
5. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
6. Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma.
Labrinidis A; Diamond P; Martin S; Hay S; Liapis V; Zinonos I; Sims NA; Atkins GJ; Vincent C; Ponomarev V; Findlay DM; Zannettino AC; Evdokiou A
Clin Cancer Res; 2009 Mar; 15(6):1998-2009. PubMed ID: 19276263
[TBL] [Abstract][Full Text] [Related]
7. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
8. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.
Faict S; Muller J; De Veirman K; De Bruyne E; Maes K; Vrancken L; Heusschen R; De Raeve H; Schots R; Vanderkerken K; Caers J; Menu E
Blood Cancer J; 2018 Nov; 8(11):105. PubMed ID: 30409995
[TBL] [Abstract][Full Text] [Related]
9. Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation.
McMillin DW; Delmore J; Negri J; Ooi M; Klippel S; Miduturu CV; Gray NS; Richardson PG; Anderson KC; Kung AL; Mitsiades CS
PLoS One; 2011; 6(7):e20226. PubMed ID: 21750699
[TBL] [Abstract][Full Text] [Related]
10. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
11. KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts.
Miki H; Ozaki S; Nakamura S; Oda A; Amou H; Ikegame A; Watanabe K; Hiasa M; Cui Q; Harada T; Fujii S; Nakano A; Kagawa K; Takeuchi K; Yata K; Sakai A; Abe M; Matsumoto T
Br J Haematol; 2011 Nov; 155(3):328-39. PubMed ID: 21902681
[TBL] [Abstract][Full Text] [Related]
12. Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents.
Soodgupta D; Zhou H; Beaino W; Lu L; Rettig M; Snee M; Skeath J; DiPersio JF; Akers WJ; Laforest R; Anderson CJ; Tomasson MH; Shokeen M
J Nucl Med; 2016 Apr; 57(4):640-5. PubMed ID: 26742713
[TBL] [Abstract][Full Text] [Related]
13. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.
Dairaghi DJ; Oyajobi BO; Gupta A; McCluskey B; Miao S; Powers JP; Seitz LC; Wang Y; Zeng Y; Zhang P; Schall TJ; Jaen JC
Blood; 2012 Aug; 120(7):1449-57. PubMed ID: 22618707
[TBL] [Abstract][Full Text] [Related]
14. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
[TBL] [Abstract][Full Text] [Related]
15. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
[TBL] [Abstract][Full Text] [Related]
16. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis.
Mori Y; Shimizu N; Dallas M; Niewolna M; Story B; Williams PJ; Mundy GR; Yoneda T
Blood; 2004 Oct; 104(7):2149-54. PubMed ID: 15138161
[TBL] [Abstract][Full Text] [Related]
17. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
18. Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity.
Sabol HM; Ferrari AJ; Adhikari M; Amorim T; McAndrews K; Anderson J; Vigolo M; Lehal R; Cregor M; Khan S; Cuevas PL; Helms JA; Kurihara N; Srinivasan V; Ebetino FH; Boeckman RK; Roodman GD; Bellido T; Delgado-Calle J
Cancer Res; 2021 Oct; 81(19):5102-5114. PubMed ID: 34348968
[TBL] [Abstract][Full Text] [Related]
19. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
20. Systemic modeling myeloma-osteoclast interactions under normoxic/hypoxic condition using a novel computational approach.
Ji Z; Wu D; Zhao W; Peng H; Zhao S; Huang D; Zhou X
Sci Rep; 2015 Aug; 5():13291. PubMed ID: 26282073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
